Literature DB >> 17327339

Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease.

Annunziata Lapolla1, Francesco Piarulli, Giovanni Sartore, Antonio Ceriello, Eugenio Ragazzi, Rachele Reitano, Lorenzo Baccarin, Barbara Laverda, Domenico Fedele.   

Abstract

OBJECTIVE: Advanced glycation end products (AGEs), pentosidine and malondialdehyde (MDA), are elevated in type 2 diabetic subjects with coronary and carotid angiopathy. We investigated the relationship of AGEs, MDA, total reactive antioxidant potentials (TRAPs), and vitamin E in type 2 diabetic patients with and without peripheral artery disease (PAD). RESEARCH DESIGN AND METHODS: AGEs, pentosidine, MDA, TRAP, vitamin E, and ankle-brachial index (ABI) were measured in 99 consecutive type 2 diabetic subjects and 20 control subjects.
RESULTS: AGEs, pentosidine, and MDA were higher and vitamin E and TRAP were lower in patients with PAD (ABI <0.9) than in patients without PAD (ABI >0.9) (P < 0.001). After multiple regression analysis, a correlation between AGEs and pentosidine, as independent variables, and ABI, as the dependent variable, was found in both patients with and without PAD (r = 0.9198, P < 0.001 and r = 0.5764, P < 0.001, respectively) but not in control subjects. When individual regression coefficients were evaluated, only that due to pentosidine was confirmed as significant. For patients with PAD, considering TRAP, vitamin E, and MDA as independent variables and ABI as the dependent variable produced an overall significant regression (r = 0.6913, P < 0.001). The regression coefficients for TRAP and vitamin E were not significant, indicating that the model is best explained by a single linear regression between MDA and ABI. These findings were also confirmed by principal component analysis.
CONCLUSIONS: Results show that pentosidine and MDA are strongly associated with PAD in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327339     DOI: 10.2337/dc06-1508

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  34 in total

1.  Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease.

Authors:  Anand Prasad; James R Lane; Sotirios Tsimikas; Ehtisham Mahmud; Srikrishna Khandrika; Peter Bekker; Manjusha Ilapakurti; Dan Nguyen; Amir Ravandi; Travis Israel
Journal:  Int J Angiol       Date:  2015-03-23

Review 2.  Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?

Authors:  Daniele Pastori; Roberto Carnevale; Pasquale Pignatelli
Journal:  Intern Emerg Med       Date:  2013-09-22       Impact factor: 3.397

3.  Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro.

Authors:  Savita Bansal; Manushi Siddarth; Diwesh Chawla; Basu D Banerjee; S V Madhu; Ashok K Tripathi
Journal:  Mol Cell Biochem       Date:  2011-11-03       Impact factor: 3.396

4.  Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects.

Authors:  Hang Hu; Chun-mao Han; Xin-lei Hu; Wan-lan Ye; Wen-juan Huang; Andries J Smit
Journal:  J Zhejiang Univ Sci B       Date:  2012-05       Impact factor: 3.066

5.  High serum level of methylglyoxal-derived AGE, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine, independently relates to renal dysfunction.

Authors:  Kenji Ito; Noriyuki Sakata; Ryoji Nagai; Jun-Ichi Shirakawa; Maho Watanabe; Ayako Mimata; Yasuhiro Abe; Tetsuhiko Yasuno; Yoshie Sasatomi; Katsuhisa Miyake; Naoko Ueki; Aki Hamauchi; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2016-06-25       Impact factor: 2.801

6.  Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients.

Authors:  F Piarulli; G Sartore; A Ceriello; E Ragazzi; R Reitano; L Nollino; C Cosma; D Fedele; A Lapolla
Journal:  Diabetologia       Date:  2009-04-29       Impact factor: 10.122

Review 7.  Advanced glycation end products: role in pathology of diabetic cardiomyopathy.

Authors:  Vijaya Lakshmi Bodiga; Sasidhar Reddy Eda; Sreedhar Bodiga
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

8.  Role of advanced glycation end products in cardiovascular disease.

Authors:  Zeinab Hegab; Stephen Gibbons; Ludwig Neyses; Mamas A Mamas
Journal:  World J Cardiol       Date:  2012-04-26

9.  Effects of olmesartan on arterial stiffness in rats with chronic renal failure.

Authors:  Yao-Chen Chuang; Ming-Shiou Wu; Yi-Kai Su; Kwang-Ming Fang
Journal:  Cardiovasc Diabetol       Date:  2012-06-13       Impact factor: 9.951

10.  Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study.

Authors:  Anna Birukov; Rafael Cuadrat; Elli Polemiti; Fabian Eichelmann; Matthias B Schulze
Journal:  Cardiovasc Diabetol       Date:  2021-06-27       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.